Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: CSP #465 - Glycemic Control and Complications in Diabetes Mellitus Type 2 (VADT)
Brief Summary: This study is a prospective, 2-arm, randomized controlled trial to determine whether glycemic control, achieved through intensification of treatment, is effective in preventing clinical macrovascular complications in patients with type 2 DM who are no longer responsive to oral agents alone. The study consists of a two-year accrual period and five years of follow-up (7 years total) of 1700 patients across 20 centers. We have powered the study to detect a 21% reduction in the primary event rate. Additional study goals are to determine whether the expenditures, discomfort, and adverse effects associated with intensive intervention are justified in terms of their clinical benefits, considering both macrovascular and microvascular complications.


Options:
A: Arm Label: Standard glycemic control; Type: ACTIVE_COMPARATOR; Interventions: Drug: Insulin, Drug: Glimepiride, Drug: Rosiglitazone, Drug: Metformin | Arm Label: Intensive glycemic control; Type: EXPERIMENTAL; Interventions: Drug: Insulin, Drug: Glimepiride, Drug: Rosiglitazone, Drug: Metformin | Intervention Type: DRUG; Name: Insulin; Assigned to Arm(s): Intensive glycemic control, Standard glycemic control | Intervention Type: DRUG; Name: Glimepiride; Assigned to Arm(s): Intensive glycemic control, Standard glycemic control | Intervention Type: DRUG; Name: Rosiglitazone; Assigned to Arm(s): Intensive glycemic control, Standard glycemic control | Intervention Type: DRUG; Name: Metformin; Assigned to Arm(s): Intensive glycemic control, Standard glycemic control
B: Arm Label: Anti-VEGF+Deferred PRP; Type: EXPERIMENTAL; Interventions: Drug: 0.5-mg Ranibizumab, Other: Deferred panretinal photocoagulation | Arm Label: Prompt PRP; Type: ACTIVE_COMPARATOR; Interventions: Other: Prompt Panretinal Photocoagulation | Intervention Type: OTHER; Name: Prompt Panretinal Photocoagulation; Assigned to Arm(s): Prompt PRP | Intervention Type: DRUG; Name: 0.5-mg Ranibizumab; Assigned to Arm(s): Anti-VEGF+Deferred PRP | Intervention Type: OTHER; Name: Deferred panretinal photocoagulation; Assigned to Arm(s): Anti-VEGF+Deferred PRP
C: Arm Label: Blood pressure; Type: PLACEBO_COMPARATOR; Interventions: Drug: Perindopril-indapamide | Arm Label: Glucose control; Type: OTHER; Interventions: Drug: Gliclazide MR-based glucose lowering | Intervention Type: DRUG; Name: Perindopril-indapamide; Assigned to Arm(s): Blood pressure | Intervention Type: DRUG; Name: Gliclazide MR-based glucose lowering; Assigned to Arm(s): Glucose control
D: Arm Label: Intensive glycemia control; Type: EXPERIMENTAL; Interventions: Drug: Hypoglycemic Agents | Arm Label: Standard glycemia control; Type: ACTIVE_COMPARATOR; Interventions: Drug: Standard glycemia control | Arm Label: Intensive BP control; Type: EXPERIMENTAL; Interventions: Drug: Intensive BP treatment | Arm Label: Standard BP control; Type: ACTIVE_COMPARATOR; Interventions: Drug: Standard BP control | Arm Label: Fibrate; Type: EXPERIMENTAL; Interventions: Drug: Fenofibrate, Drug: Simvastatin | Arm Label: Fibrate Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Simvastatin, Drug: Placebo | Intervention Type: DRUG; Name: Hypoglycemic Agents; Assigned to Arm(s): Intensive glycemia control | Intervention Type: DRUG; Name: Standard glycemia control; Assigned to Arm(s): Standard glycemia control | Intervention Type: DRUG; Name: Intensive BP treatment; Assigned to Arm(s): Intensive BP control | Intervention Type: DRUG; Name: Standard BP control; Assigned to Arm(s): Standard BP control | Intervention Type: DRUG; Name: Fenofibrate; Assigned to Arm(s): Fibrate | Intervention Type: DRUG; Name: Simvastatin; Assigned to Arm(s): Fibrate, Fibrate Placebo | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Fibrate Placebo

Answer: A